

Syngene

▶
Relentless.
Reliable.
Responsible.





Contents

Relentless	2	Corporate Information	34
Reliable	4	Board of Directors	35
Responsible	6	Executive Committee & Senior Leadership Team	38
The Syngene Advantage	8	Board, Committees and Others	39
Journey of Excellence	10	Board's Report	41
Taking the Business of our Customers Ahead	12	Annexures to the Board's Report	48
Syngene in Numbers	14	Management Discussion & Analysis	72
Robust and Resilient Business Model	16	Corporate Governance Report	79
Relentlessly Enhancing Multi-Year Value	18	Business Responsibility Report	94
Responsibly Enhancing Multi-Quarter Performance (during 2016-17)	19	Financial Statements	103
Reliably Enhancing Business Performance	21	Notice to AGM	147
Strengthening our Service Repertoire	24	Instructions for e-voting	154
Upcoming Facilities	26		
Support Functions	27		



Relentless.
Reliable.
Responsible.

Research is a journey. A journey of relentless quest for finding reliable solutions in a responsible manner. We, at Syngene, are committed to partnering R&D-focused organizations across the globe in their research journey. Working relentlessly on cutting-edge scientific projects. Developing innovative and reliable solutions. To address some of their critical scientific problems in the most responsible and responsive manner.





Relentless





Syngene has, over the last two decades, relentlessly invested its intellectual and financial capital in building expertise in cutting-edge science and technology for developing innovative solutions that meet the R&D requirements of global organizations.

It was incorporated in 1993 with the objective of providing world-class R&D outsourced services to science-focused organizations across the globe, and becoming a leading global CRO player.


Today, Syngene has emerged as India's largest and the only listed CRO.

- Providing R&D services to multiple industries including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, agrochemical, cosmetics and specialty chemicals.
- Providing a range of discovery and development services for Novel Chemical Entities (NCEs) across multiple domains – small molecules, large molecules (biologics), antibody drug conjugates and oligonucleotides.
- Offering multiple engagement points across a molecule's discovery and development journey.
- Offering an attractive variable cost alternative to the conventional fixed cost R&D model.



Reliable





Over the last two decades, Syngene, through a comprehensive strategy of strengthening research capabilities and focusing on client satisfaction, has become a reliable and trustworthy partner for global innovator companies by continually expanding its service offerings to meet their evolving R&D needs.

Syngene implemented various strategic initiatives during FY2016-17.

- Introduced bioinformatics services by acquiring the systems biology and pharma bioinformatics services of Strand Lifesciences, reinforcing its position as a 'One-Stop' solution provider.
- Strengthened biology service capabilities by adding new services like Next Generation Sequencing Technology Platform for genomics, transcriptomics and microbiomics work.
- Expanded competences in the pharmacological study of niche therapeutic segments like oncology, cardio-metabolic disorders, neurology, kidney disease and inflammation.
- Introduced viral testing services by setting up a dedicated viral testing facility, which will augment company's biologics capabilities

Syngene's 'reliable partner' position is strongly reflected in its growing client base and increasing number of dedicated R&D centers. The company had 293 clients and built two new dedicated R&D centers in FY2016-17.

Responsible





In an endeavor to become a responsible partner for global R&D-focused organizations, Syngene has constantly aligned its operations with global best practices. The company has meticulously structured its operations to meet global compliance and governance standards.

Syngene's stringent compliance and governance standards are reinforced across various levels.

- 'Zero tolerance' approach to data integrity and IP protection through investments in IT framework has ensured not one instance of breach in its two decades of existence.
- Impeccable track record of quality and regulatory compliance.
- Sustained on-time delivery of projects.

Syngene has always believed in maintaining an open and transparent line of communication with clients. In FY2016-17, when a fire broke out at one of our R&D facilities, we immediately and responsibly communicated this to all clients, along with its impact on their on-going projects. As a responsible business partner, we worked uncompromisingly to shift on-going projects to alternative locations, minimizing project disruption.

This sensitive responsiveness reinforced Syngene's position as a trusted partner in meeting the evolving R&D needs of global clients. This was strongly reflected in the fact that except one all other clients continued their association with Syngene following the fire.

The Syngene Advantage

